Hematologic Malignancies | Special Reports

In the Pipeline: Potential New Treatments for AML

July 09, 2014

Clinical Articles

In the spring of 2014, a search of the clinicaltrials.gov web site with the key words acute myeloid leukemia and phase II, III returned a list of just over 340 open studies. Most of those trials involving novel agents can be grouped into 1 of 2 general categories: immunomodulators or kinase inhibitors.

Epidemiology in B-Cell Malignancies

July 09, 2014

Clinical Articles

B-cell malignancies include non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL). NHLs are a heterogeneous group of more than 30 cancers of B lymphocytes and T lymphocytes.

Pathogenesis of Follicular Lymphoma

July 09, 2014

Clinical Articles

Follicular lymphoma is the malignancy of germinal center B cells in the lymph nodes. It is the second most commonly diagnosed non-Hodgkin’s lymphoma, accounting for approximately 35% of all such cases.

BCL-2 Inhibitor Combo May Offer Remissions in CLL

July 08, 2014

Clinical Articles

Creating new treatment options for CLL, particularly for high-risk patient populations such as those with fludarabine-refractory disease or with 17p deletions, is the goal of an intense effort by clinical researchers and pharmaceutical companies.